MARKET

LYEL

LYEL

Lyell Immunopharma, Inc.
NASDAQ
14.30
-1.34
-8.57%
After Hours: 14.30 0 0.00% 16:10 11/13 EST
OPEN
15.54
PREV CLOSE
15.64
HIGH
15.76
LOW
14.20
VOLUME
236.66K
TURNOVER
--
52 WEEK HIGH
45.00
52 WEEK LOW
7.20
MARKET CAP
351.57M
P/E (TTM)
-1.2178
1D
5D
1M
3M
1Y
5Y
1D
Lyell Immunopharma registers to sell 7.43M shares of common stock for holders
TipRanks · 5h ago
Lyell Immunopharma Files Prospectus For Resale Of 7,428,040 Shares By Selling Stockholders
Benzinga · 5h ago
Lyell Immunopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 15h ago
Lyell Immunopharma Price Target Cut to $39.00/Share From $45.00 by HC Wainwright & Co.
Dow Jones · 15h ago
HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $39
Benzinga · 15h ago
Weekly Report: what happened at LYEL last week (1102-1106)?
Weekly Report · 4d ago
Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Lyell Immunopharma (LYEL) and Alector (ALEC)
TipRanks · 11/06 12:50
Lyell: Upgrade To 'Buy' On Ronde-Cel Advancement LBCL And $80 Million Funding Boost
Seeking Alpha · 11/05 18:09
More
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Webull offers Lyell Immunopharma Inc stock information, including NASDAQ: LYEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYEL stock methods without spending real money on the virtual paper trading platform.